Genetic deletion of FAP in a KPC model led to decreased tumor growth, with improved immune surveillance and synergy with anti PD-1 and anti CTLA-4 therapies, an effect that resulted from a reduction in CAF-mediated CXCL12 secretion. Here, CXCL12 is linked to neoplasm.